---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T10:39:14.978873'
end_time: '2025-12-27T10:49:09.371865'
duration_seconds: 594.39
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: KCTD4
  gene_symbol: KCTD4
  uniprot_accession: Q8WVF5
  protein_description: 'RecName: Full=BTB/POZ domain-containing protein KCTD4;'
  gene_info: Name=KCTD4;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BTB/POZ_dom. (IPR000210); KCTD4_C. (IPR045740); SKP1/BTB/POZ_sf.
    (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8WVF5
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD4;
- **Gene Information:** Name=KCTD4;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); KCTD4_C. (IPR045740); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD4** (gene ID: KCTD4, UniProt: Q8WVF5) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8WVF5
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD4;
- **Gene Information:** Name=KCTD4;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); KCTD4_C. (IPR045740); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD4** (gene ID: KCTD4, UniProt: Q8WVF5) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive research report: Human KCTD4 (UniProt: Q8WVF5)

Executive verification and scope
- Gene/protein identity: KCTD4 unequivocally refers to the human BTB/POZ (T1-type) domain-containing protein “BTB/POZ domain-containing protein KCTD4” (UniProt Q8WVF5). Family-level analyses place KCTD4 within the potassium channel tetramerization domain (KCTD) protein family bearing an N‑terminal BTB/T1 domain (a BTB/POZ fold) (teng2019kctdanew pages 4-7, sokolina2014humangpcrinteractome pages 53-56).
- Organism: Homo sapiens (Human) confirmed (family and domain context; UniProt accession cited above) (teng2019kctdanew pages 4-7, sokolina2014humangpcrinteractome pages 53-56).
- Domain/family alignment: KCTD proteins share an N‑terminal BTB/T1 domain adapted for oligomerization; this matches the provided UniProt domain set (BTB/POZ/T1) (teng2019kctdanew pages 4-7, sokolina2014humangpcrinteractome pages 53-56).
- Ambiguity check: Searches did not reveal conflicting human gene symbols overlapping with non-human KCTD4 entries; evidence indicates limited KCTD4-specific literature relative to other KCTDs, so we prioritize recent KCTD family studies with explicit KCTD4 mentions (sokolina2014humangpcrinteractome pages 53-56, liao2023kctd5formsheterooligomeric pages 9-10, balasco2024acomprehensiveanalysis pages 8-9).

Key concepts and definitions
- KCTD family and BTB/T1 domain: KCTDs are intracellular proteins whose N‑terminal BTB/T1 domain is structurally related to BTB/POZ folds and adapted to drive homo-oligomerization; many KCTDs act as substrate adaptors for Cullin3 (Cul3)-RING E3 ligases, though Cul3 binding is member-specific (teng2019kctdanew pages 4-7, david2018gababreceptorassociatedkctd pages 14-17, sokolina2014humangpcrinteractome pages 53-56). The GABAB-associated KCTD subclade is restricted to KCTD8/12/16 and mediates receptor kinetics via direct receptor tail and G protein interactions; KCTD4 is not part of this subclade (david2018gababreceptorassociatedkctd pages 14-17, teng2019kctdanew pages 4-7).
- Functional paradigms in the family: Two dominant mechanistic themes are (i) CRL3 (Cul3-based) ubiquitin ligase adaptor functions mediated by BTB or alternative motifs, and (ii) modulation of GPCR signaling either as GABAB auxiliary subunits (KCTD8/12/16) or via interactions with Gβγ affecting cAMP signaling (shown for several KCTDs) (teng2019kctdanew pages 4-7, david2018gababreceptorassociatedkctd pages 14-17, sloan2023multiplepotassiumchannel pages 7-10).

| Aspect | Finding (concise) | Evidence type | Year | Key details / statistics | Source (DOI/URL if available) |
|---|---|---:|---:|---|---|
| Identity verification (human, BTB/POZ) | KCTD4 corresponds to human UniProt Q8WVF5; member of KCTD/BTB family (BTB/T1 domain present). | Review/annotation | 2019, 2014 | Family-level annotation places KCTD4 in KCTD family with N-terminal BTB/T1 motif typical of KCTDs (family roles summarized). | (teng2019kctdanew pages 4-7, sokolina2014humangpcrinteractome pages 53-56) |
| Domain architecture | N-terminal BTB/T1 (BTB/POZ) domain plus variable C-terminal region; C-terminal domains often divergent across family. | Review / structural analysis | 2019, 2024 | C-terminal domains vary; BTB mediates oligomerization and can mediate protein interactions in other KCTDs. | (teng2019kctdanew pages 4-7, balasco2024acomprehensiveanalysis pages 8-9) https://doi.org/10.3390/ijms25031881 (balasco2024acomprehensiveanalysis pages 8-9) |
| Oligomeric state | Assigned/predicted pentameric assembly for KCTD4. | In silico / structural clustering | 2024 | Structural clustering (AlphaFold/analysis) groups KCTD4 in a pentameric cluster (Cluster 4). | (balasco2024acomprehensiveanalysis pages 8-9) https://doi.org/10.3390/ijms25031881 |
| Predicted/observed Cullin‑3 (Cul3) binding | KCTD4 predicted NOT to form a stable Cul3 complex (AlphaFold models gave a 'meaningless complex' / poor PAE). Family members variably bind Cul3. | In silico (prediction) + family-level review | 2024, 2019 | AF-based modeling failed to produce reliable KCTD4–Cul3 complex; many other KCTDs are Cul3 adaptors but binding is KCTD-specific. | (balasco2024acomprehensiveanalysis pages 8-9, teng2019kctdanew pages 4-7) https://doi.org/10.3390/ijms25031881 (balasco2024acomprehensiveanalysis pages 8-9) |
| GABAB-subclade membership | KCTD4 is NOT among the established GABAB-associated KCTDs (those are KCTD8/12/16 subclade). | Review / family analysis | 2018–2019 | GABAB auxiliary subunits are a restricted subclade (KCTD8/12/16); literature does not place KCTD4 in this group. | (david2018gababreceptorassociatedkctd pages 14-17, teng2019kctdanew pages 4-7) |
| Interactions with Gβγ (functional assays) | No direct experimental evidence that KCTD4 binds Gβγ; several other KCTDs (e.g., KCTD2/5/17) do bind Gβγ and affect cAMP signaling. | Primary (family-level assays) / negative for KCTD4 | 2023 | Functional IP/BRET and cellular assays show Gβγ binding for multiple KCTDs; no published KCTD4-specific Gβγ binding reported in surveyed sources. | (sloan2023multiplepotassiumchannel pages 7-10, sokolina2014humangpcrinteractome pages 53-56) https://doi.org/10.1016/j.jbc.2023.102924 (sloan2023multiplepotassiumchannel pages 7-10) |
| Hetero-oligomerization (family context) | KCTD5 can form hetero-oligomeric complexes with various KCTDs, reported to include interactions with KCTD4 in co‑IP / BRET assays. | Primary (co‑IP, BRET) | 2023 | Experimental cell-based interaction assays (co-IP, BRET) demonstrate KCTD5 hetero-oligomerization across family members, including KCTD4 as a detected partner. | (liao2023kctd5formsheterooligomeric pages 9-10) https://doi.org/10.3390/ijms241814317 (liao2023kctd5formsheterooligomeric pages 9-10) |
| Subcellular localization | KCTD family proteins are intracellular/cytosolic; no robust KCTD4-specific localization experimental data found in surveyed sources. | Review / family annotation | 2014, 2018 | Family-level descriptions describe KCTDs as soluble intracellular proteins; KCTD4-specific localization not reported in available texts. | (sokolina2014humangpcrinteractome pages 53-56, david2018gababreceptorassociatedkctd pages 14-17) |
| Expression evidence (HLA‑I peptidome / proteomics) | KCTD4-derived peptide(s) observed in an HLA class I peptidome from a hepatocellular carcinoma cell line (proteomics detection). | Primary proteomics | 2007 | KCTD4 (Q8WVF5) peptides were detected in an HLA‑I immunopeptidome dataset (listed among detected proteins/peptides). | (alvarez2007analysisofthe pages 7-9) https://doi.org/10.1002/prca.200600388 (alvarez2007analysisofthe pages 7-9) |
| Pathway involvement (GPCR / CRL3 context, family level) | KCTD family implicated in GPCR modulation (GABAB, Gβγ regulation) and as potential Cul3 adaptors (CRL3); KCTD4 function in these pathways is unconfirmed. | Reviews / primary family studies | 2018–2019, 2023 | Family-level mechanistic data: some KCTDs act as CRL3 substrate adapters and/or GABAB auxiliary subunits; applicability to KCTD4 must be determined experimentally. | (david2018gababreceptorassociatedkctd pages 14-17, teng2019kctdanew pages 4-7, sloan2023multiplepotassiumchannel pages 7-10) |
| Disease associations (KCTD4-specific vs family-level) | No robust, reproducible KCTD4-specific disease associations reported in surveyed sources; KCTD family members broadly linked to neurodevelopmental/neuropsychiatric disorders and cancers. | Review / proteomics (family-level) | 2019, 2007 | Family-level links: KCTD members implicated in NDDs, cancer, metabolic roles; isolated proteomic detection of KCTD4 in tumor-derived peptide data but no causal/clinical studies for KCTD4 found. | (teng2019kctdanew pages 4-7, alvarez2007analysisofthe pages 7-9) |
| Notable 2023–2024 developments relevant to KCTD4 context | 2023: experimental evidence of extensive KCTD hetero-oligomerization (including KCTD4 as a KCTD5 interactor); 2024: structural/AlphaFold analysis predicts KCTD4 pentamer and poor Cul3 binding. | Primary / in silico | 2023–2024 | Key updates: Liao et al. (2023) experimentally mapped hetero-oligomers; Balasco et al. (2024) provided AF‑based KCTD–Cul3 interaction landscape placing KCTD4 in a pentameric, likely non‑Cul3‑binding cluster. | (liao2023kctd5formsheterooligomeric pages 9-10, balasco2024acomprehensiveanalysis pages 8-9) https://doi.org/10.3390/ijms241814317 (liao2023kctd5formsheterooligomeric pages 9-10), https://doi.org/10.3390/ijms25031881 (balasco2024acomprehensiveanalysis pages 8-9) |


*Table: Concise, sourced evidence table summarizing what is known about human KCTD4 (UniProt Q8WVF5), covering identity, domains, oligomeric state, interactions, localization, expression, pathway context, disease links, and key 2023–2024 updates. Each row cites the specific sources used (context IDs).*

Recent developments (2023–2024) and latest research
- Structural/Cul3 binding landscape (2024): An in silico structural survey using AlphaFold-guided modeling reported that KCTD4 forms a pentameric assembly (Cluster 4) but does not produce a reliable, meaningful complex with Cul3; predicted KCTD4–Cul3 complexes showed poor confidence/PAE profiles relative to confirmed Cul3-interacting KCTDs (International Journal of Molecular Sciences, 2024; DOI: https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).
- Hetero-oligomerization within the family (2023): KCTD5 was shown to form hetero-oligomeric complexes with multiple KCTD members across clades. The interaction dataset from co-IP and BRET assays included KCTD4 as a hetero-oligomeric partner of KCTD5, indicating that KCTD4 can participate in mixed KCTD assemblies (Int. J. Mol. Sci., 2023; DOI: https://doi.org/10.3390/ijms241814317) (liao2023kctd5formsheterooligomeric pages 9-10).
- GPCR/Gβγ regulatory context (2023): Multiple KCTDs (e.g., KCTD2/5/17) were demonstrated to bind Gβγ and suppress cAMP sensitization in reconstituted systems and neurons. KCTD4 was included as a phylogenetically distinct comparator in neuronal assays, but the study did not present direct biochemical evidence of KCTD4–Gβγ binding; thus, KCTD4’s Gβγ interaction remains unproven (Journal of Biological Chemistry, 2023; DOI: https://doi.org/10.1016/j.jbc.2023.102924) (sloan2023multiplepotassiumchannel pages 7-10).

Molecular function, interactions, and pathways (KCTD4-specific and by-close analogy)
- Oligomeric state: KCTD4 is predicted to assemble as a pentamer, consistent with the predominant pentameric architecture found in many KCTDs and supported by the 2024 structural clustering (balasco2024acomprehensiveanalysis pages 8-9).
- Cul3/E3-ligase adaptor potential: Current AF-based modeling suggests KCTD4 is unlikely to form a stable Cul3 complex, in contrast to many Cul3-binding KCTDs; therefore, a primary role as a Cul3 adaptor remains unsubstantiated for KCTD4 (balasco2024acomprehensiveanalysis pages 8-9). Family reviews emphasize that Cul3 binding is not universal across BTB proteins, so the BTB fold alone does not guarantee Cul3 engagement (teng2019kctdanew pages 4-7, david2018gababreceptorassociatedkctd pages 14-17).
- GABAB receptor machinery: KCTD4 is not part of the GABAB auxiliary subunit subclade (KCTD8/12/16). KCTD8/16 can bind Cul3 via non-BTB C-terminal H2 regions and link CRL3 to GABAB, a mechanism not known for KCTD4 (david2018gababreceptorassociatedkctd pages 35-39, david2018gababreceptorassociatedkctd pages 14-17).
- Gβγ and GPCR signaling: Direct binding of KCTD4 to Gβγ has not been established in the surveyed 2023–2024 work; other KCTDs clearly bind Gβγ and attenuate cAMP sensitization, highlighting a plausible but unproven analogy for KCTD4 (sloan2023multiplepotassiumchannel pages 7-10). 
- Hetero-oligomeric assemblies: KCTD5–KCTD4 associations detected by co-IP/BRET suggest KCTD4 can contribute to mixed KCTD complexes, potentially influencing the assembly and localization of larger KCTD networks (liao2023kctd5formsheterooligomeric pages 9-10).

Cellular localization and expression
- Localization: KCTD proteins are soluble intracellular proteins; KCTD4-specific localization was not reported in the reviewed texts. Thus, cytosolic/intracellular residence is inferred at family level pending direct KCTD4 mapping (sokolina2014humangpcrinteractome pages 53-56, david2018gababreceptorassociatedkctd pages 14-17).
- Expression evidence from immunopeptidomics: A proteomics study of an HLA class I peptidome from a hepatocellular carcinoma line listed a KCTD4 (Q8WVF5) peptide among identified antigens, indicating expression sufficient for antigen processing and presentation in that context (Proteomics Clinical Applications, 2007; DOI: https://doi.org/10.1002/prca.200600388) (alvarez2007analysisofthe pages 7-9).

Disease links, applications, and real-world implementations
- Disease associations (KCTD4-specific): Robust disease-specific literature for KCTD4 is scarce in the surveyed sources. The HLA peptidome detection provides evidence of expression in a tumor cell line setting but does not establish causal roles (alvarez2007analysisofthe pages 7-9).
- Family-level disease context: KCTD family proteins are linked to neurodevelopmental/neuropsychiatric disorders and cancers; however, these associations are member-specific, and extrapolation to KCTD4 requires direct evidence (teng2019kctdanew pages 4-7). GABAB-associated KCTDs and Cul3-interacting KCTDs have clearer roles; KCTD4 does not fall squarely into either evidenced category (david2018gababreceptorassociatedkctd pages 14-17, balasco2024acomprehensiveanalysis pages 8-9).
- Practical implications: The 2023 demonstration that KCTD4 can hetero-oligomerize with KCTD5 suggests potential for KCTD4 to modulate multi-KCTD complexes implicated in GPCR or ubiquitin signaling in a tissue-specific manner, but concrete pathway-level applications for KCTD4 remain to be defined experimentally (liao2023kctd5formsheterooligomeric pages 9-10).

Expert opinions and authoritative analyses
- Authoritative reviews emphasize the diversity of KCTD functions and caution against assuming Cul3 binding based solely on the BTB fold. Structural and biochemical validation is required member-by-member, a principle that applies directly to KCTD4 (teng2019kctdanew pages 4-7, david2018gababreceptorassociatedkctd pages 14-17, sokolina2014humangpcrinteractome pages 53-56). 
- The AlphaFold-guided Cul3 interaction survey (2024) provides a current, systematic perspective that KCTD4 is among likely non-interactors with Cul3—an inference that narrows functional hypotheses and focuses future experimental work (balasco2024acomprehensiveanalysis pages 8-9).

Relevant statistics and data
- 2024 AF-based survey: Reliable KCTD–Cul3 models were obtained for 15 KCTDs known to interact with Cul3; KCTD4 was categorized among non-interactors with “meaningless” complex predictions (qualitative PAE/confidence assessment) (balasco2024acomprehensiveanalysis pages 8-9).
- 2023 hetero-oligomerization screen: KCTD5 formed interactions with numerous KCTDs in co‑IP and BRET; KCTD4 was among detected partners, indicating cross-family hetero-assembly potential in cells (qualitative detection in multiple assays) (liao2023kctd5formsheterooligomeric pages 9-10).
- 2023 Gβγ/cAMP studies: Multiple KCTDs demonstrated Gβγ binding and functional suppression of cAMP sensitization; KCTD4 was included as a comparator in neuronal assays without presentation of direct binding data (sloan2023multiplepotassiumchannel pages 7-10).
- 2007 immunopeptidomics: KCTD4 (Q8WVF5) peptides detected within the HLA-I repertoire of a hepatocellular carcinoma line, evidencing protein processing/presentation (catalog listing; qualitative) (alvarez2007analysisofthe pages 7-9).

Summary assessment of KCTD4 function and next steps
- Most consistent, recent evidence supports KCTD4 as a pentameric BTB/T1-domain protein capable of forming hetero-oligomeric complexes (e.g., with KCTD5), but without current evidence for stable Cul3 binding or GABAB auxiliary function. Family-level paradigms (CRL3 adaptor and GPCR/Gβγ modulation) remain plausible frameworks; however, KCTD4’s placement appears currently outside the established GABAB subclade and outside the Cul3-engaging cohort by structural prediction, narrowing the hypotheses for its primary function (balasco2024acomprehensiveanalysis pages 8-9, liao2023kctd5formsheterooligomeric pages 9-10, david2018gababreceptorassociatedkctd pages 14-17, teng2019kctdanew pages 4-7).
- Priorities for functional annotation: (i) biochemistry of KCTD4–Cul3 (co-IP, in vitro reconstitution) to confirm or refute non-binding predictions; (ii) direct tests of KCTD4–Gβγ interaction and functional effects on AC isoforms; (iii) mapping subcellular localization and interactomes across tissues; (iv) targeted expression analyses (e.g., GTEx, proteomics) and genetic association screens to identify disease links.

Cited sources with URLs and dates
- Teng et al., 2019, CNS Neuroscience & Therapeutics (review): KCTD family overview; BTB/T1 domain, oligomerization, Cul3 adaptors, and GABAB subclade context. DOI: https://doi.org/10.1111/cns.13156 (June 2019) (teng2019kctdanew pages 4-7).
- Berner (David), 2018, University of Basel (thesis/preprint): GABAB-associated KCTDs; evidence that KCTD8/16 link Cul3 via non-BTB H2 domains and recruit CRL3 to GABAB; KCTD12 not recruiting; KCTD4 not in GABAB subclade. DOI: https://doi.org/10.5451/unibas-006803142 (2018) (david2018gababreceptorassociatedkctd pages 35-39, david2018gababreceptorassociatedkctd pages 14-17).
- Sokolina, 2014 (thesis): Family-level BTB/T1 information; note on limited KCTD4-specific literature at that time. URL not provided in extract (2014) (sokolina2014humangpcrinteractome pages 53-56).
- Liao et al., 2023, International Journal of Molecular Sciences: KCTD5 forms hetero-oligomers across the KCTD family, including with KCTD4 (co‑IP and BRET). DOI: https://doi.org/10.3390/ijms241814317 (September 2023) (liao2023kctd5formsheterooligomeric pages 9-10).
- Sloan et al., 2023, Journal of Biological Chemistry: Multiple KCTDs bind Gβγ and modulate cAMP; KCTD4 included as a phylogenetically distinct comparator; no direct KCTD4–Gβγ binding reported. DOI: https://doi.org/10.1016/j.jbc.2023.102924 (March 2023) (sloan2023multiplepotassiumchannel pages 7-10).
- Balasco et al., 2024, International Journal of Molecular Sciences: AF-based KCTD–Cul3 complex modeling; KCTD4 predicted pentamer and likely Cul3 non-interactor. DOI: https://doi.org/10.3390/ijms25031881 (February 2024) (balasco2024acomprehensiveanalysis pages 8-9).
- Alvarez et al., 2007, Proteomics Clinical Applications: HLA class I peptidome from hepatocellular carcinoma line; KCTD4 (Q8WVF5) peptides detected. DOI: https://doi.org/10.1002/prca.200600388 (March 2007) (alvarez2007analysisofthe pages 7-9).

Notes on literature limitations and symbol ambiguity
- The gene symbol “KCTD4” in human (Q8WVF5) appears non-ambiguous in the surveyed corpus; however, KCTD4-specific mechanistic literature is limited. Where KCTD4-specific data were unavailable, we explicitly labeled family-level inferences and avoided unjustified extrapolation (sokolina2014humangpcrinteractome pages 53-56, teng2019kctdanew pages 4-7).

References

1. (teng2019kctdanew pages 4-7): Xinchen Teng, Abdel Aouacheria, Loïc Lionnard, Kyle A. Metz, Lucian Soane, Atsushi Kamiya, and J. Marie Hardwick. Kctd: a new gene family involved in neurodevelopmental and neuropsychiatric disorders. CNS Neuroscience & Therapeutics, 25:887-902, Jun 2019. URL: https://doi.org/10.1111/cns.13156, doi:10.1111/cns.13156. This article has 130 citations and is from a peer-reviewed journal.

2. (sokolina2014humangpcrinteractome pages 53-56): E Sokolina. Human gpcr interactome and investigation of the kctd/β2-adrenergic receptor interactions. Unknown journal, 2014.

3. (liao2023kctd5formsheterooligomeric pages 9-10): Yini Liao, Douglas C. Sloan, Josephine H. Widjaja, and Brian S. Muntean. Kctd5 forms hetero-oligomeric complexes with various members of the kctd protein family. International Journal of Molecular Sciences, 24:14317, Sep 2023. URL: https://doi.org/10.3390/ijms241814317, doi:10.3390/ijms241814317. This article has 9 citations and is from a poor quality or predatory journal.

4. (balasco2024acomprehensiveanalysis pages 8-9): Nicole Balasco, Luciana Esposito, Giovanni Smaldone, Marco Salvatore, and Luigi Vitagliano. A comprehensive analysis of the structural recognition between kctd proteins and cullin 3. International Journal of Molecular Sciences, 25:1881, Feb 2024. URL: https://doi.org/10.3390/ijms25031881, doi:10.3390/ijms25031881. This article has 12 citations and is from a poor quality or predatory journal.

5. (david2018gababreceptorassociatedkctd pages 14-17): David Berner. Gabab receptor-associated kctd proteins as molecular linkers to downstream signaling complexes. ArXiv, 2018. URL: https://doi.org/10.5451/unibas-006803142, doi:10.5451/unibas-006803142. This article has 0 citations.

6. (sloan2023multiplepotassiumchannel pages 7-10): Douglas C. Sloan, Casey E. Cryan, and Brian S. Muntean. Multiple potassium channel tetramerization domain (kctd) family members interact with gβγ, with effects on camp signaling. Journal of Biological Chemistry, 299:102924, Mar 2023. URL: https://doi.org/10.1016/j.jbc.2023.102924, doi:10.1016/j.jbc.2023.102924. This article has 23 citations and is from a domain leading peer-reviewed journal.

7. (alvarez2007analysisofthe pages 7-9): Iñaki Alvarez, Montserrat Carrascal, Francesc Canals, Laia Muixí, Joaquín Abián, and Dolores Jaraquemada. Analysis of the hla class i associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor‐specific peptides as putative targets for immunotherapy. PROTEOMICS – Clinical Applications, 1:286-298, Mar 2007. URL: https://doi.org/10.1002/prca.200600388, doi:10.1002/prca.200600388. This article has 9 citations.

8. (david2018gababreceptorassociatedkctd pages 35-39): David Berner. Gabab receptor-associated kctd proteins as molecular linkers to downstream signaling complexes. ArXiv, 2018. URL: https://doi.org/10.5451/unibas-006803142, doi:10.5451/unibas-006803142. This article has 0 citations.

## Citations

1. balasco2024acomprehensiveanalysis pages 8-9
2. sloan2023multiplepotassiumchannel pages 7-10
3. alvarez2007analysisofthe pages 7-9
4. teng2019kctdanew pages 4-7
5. sokolina2014humangpcrinteractome pages 53-56
6. david2018gababreceptorassociatedkctd pages 14-17
7. david2018gababreceptorassociatedkctd pages 35-39
8. https://doi.org/10.3390/ijms25031881
9. https://doi.org/10.1016/j.jbc.2023.102924
10. https://doi.org/10.3390/ijms241814317
11. https://doi.org/10.1002/prca.200600388
12. https://doi.org/10.1111/cns.13156
13. https://doi.org/10.5451/unibas-006803142
14. https://doi.org/10.1111/cns.13156,
15. https://doi.org/10.3390/ijms241814317,
16. https://doi.org/10.3390/ijms25031881,
17. https://doi.org/10.5451/unibas-006803142,
18. https://doi.org/10.1016/j.jbc.2023.102924,
19. https://doi.org/10.1002/prca.200600388,